VRCA
Price
$0.65
Change
+$0.02 (+3.17%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
59.38M
43 days until earnings call
VRDN
Price
$16.86
Change
-$0.91 (-5.12%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
1.34B
42 days until earnings call
Ad is loading...

VRCA vs VRDN

Header iconVRCA vs VRDN Comparison
Open Charts VRCA vs VRDNBanner chart's image
Verrica Pharmaceuticals
Price$0.65
Change+$0.02 (+3.17%)
Volume$600
Capitalization59.38M
Viridian Therapeutics
Price$16.86
Change-$0.91 (-5.12%)
Volume$24.18K
Capitalization1.34B
VRCA vs VRDN Comparison Chart
Loading...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VRCA vs. VRDN commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VRCA is a Hold and VRDN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (VRCA: $0.66 vs. VRDN: $16.86)
Brand notoriety: VRCA and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: VRCA: 30% vs. VRDN: 102%
Market capitalization -- VRCA: $59.38M vs. VRDN: $1.34B
VRCA [@Biotechnology] is valued at $59.38M. VRDN’s [@Biotechnology] market capitalization is $1.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VRCA’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • VRCA’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than VRCA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VRCA’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • VRCA’s TA Score: 4 bullish, 4 bearish.
  • VRDN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, VRCA is a better buy in the short-term than VRDN.

Price Growth

VRCA (@Biotechnology) experienced а -12.57% price change this week, while VRDN (@Biotechnology) price change was -19.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

VRCA is expected to report earnings on Feb 27, 2025.

VRDN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.34B) has a higher market cap than VRCA($59.4M). VRCA YTD gains are higher at: -6.329 vs. VRDN (-12.050). VRCA has higher annual earnings (EBITDA): -74.39M vs. VRDN (-253.41M). VRDN has more cash in the bank: 753M vs. VRCA (23M). VRDN has less debt than VRCA: VRDN (21.1M) vs VRCA (47.1M). VRCA has higher revenues than VRDN: VRCA (9.21M) vs VRDN (302K).
VRCAVRDNVRCA / VRDN
Capitalization59.4M1.34B4%
EBITDA-74.39M-253.41M29%
Gain YTD-6.329-12.05053%
P/E RatioN/AN/A-
Revenue9.21M302K3,050%
Total Cash23M753M3%
Total Debt47.1M21.1M223%
FUNDAMENTALS RATINGS
VRCA vs VRDN: Fundamental Ratings
VRCA
VRDN
OUTLOOK RATING
1..100
414
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9760
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (92) in the Biotechnology industry is in the same range as VRCA (95) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to VRCA’s over the last 12 months.

VRDN's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew somewhat faster than VRCA’s over the last 12 months.

VRDN's SMR Rating (98) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to VRCA’s over the last 12 months.

VRDN's Price Growth Rating (60) in the Biotechnology industry is somewhat better than the same rating for VRCA (97) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew somewhat faster than VRCA’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VRCAVRDN
RSI
ODDS (%)
Bullish Trend 7 days ago
90%
Bullish Trend 7 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
80%
Bearish Trend 7 days ago
85%
Momentum
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
85%
MACD
ODDS (%)
Bullish Trend 7 days ago
89%
Bullish Trend 7 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
86%
Bullish Trend 12 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 27 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
77%
N/A
Aroon
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OLMA5.140.30
+6.20%
Olema Pharmaceuticals
MATH1.520.05
+3.44%
Metalpha Technology Holding Limited
ARI8.830.22
+2.56%
Apollo Commercial Real Estate Finance
ESNT56.601.09
+1.96%
Essent Group Ltd
RELX46.080.18
+0.39%
Relx PLC

VRCA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with TCBP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then TCBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
+3.26%
TCBP - VRCA
41%
Loosely correlated
+1.50%
SCPX - VRCA
38%
Loosely correlated
-2.11%
ACOG - VRCA
33%
Loosely correlated
-3.45%
ABCL - VRCA
32%
Poorly correlated
-7.67%
PBYI - VRCA
32%
Poorly correlated
+0.32%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with ALLO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-5.12%
ALLO - VRDN
51%
Loosely correlated
-1.54%
FATE - VRDN
48%
Loosely correlated
-2.71%
AURA - VRDN
47%
Loosely correlated
+0.80%
CRBU - VRDN
45%
Loosely correlated
+0.65%
ABCL - VRDN
45%
Loosely correlated
-7.67%
More